Search for: "Watson Laboratories Inc."
Results 61 - 80
of 133
Sort by Relevance
|
Sort by Date
4 Dec 2011, 8:52 pm
• Defendants: Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Watson Laboratories, Inc. [read post]
1 Dec 2011, 2:02 pm
(NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz(R) oral contraceptive product. [read post]
1 Nov 2011, 6:08 am
Inc. have experienced problems. [read post]
9 Oct 2011, 9:37 pm
• Defendants: Watson Pharmaceuticals Inc.; Watson Laboratories Inc.; Watson Pharma Inc.; Watson Laboratories Inc. - Florida Infringement of U.S. [read post]
30 Sep 2011, 2:32 pm
Barr Laboratories, Inc., 386 F.3d 485, 485 (2d Cir. 2004) [read post]
18 Jul 2011, 5:16 pm
(“Cephalon”) on March 15, 2011 challenging FDA’s January 7, 2011 approval of Watson Laboratories, Inc. [read post]
17 Jul 2011, 9:17 pm
Watson Pharmaceuticals et al. 1:11-cv-00607; filed July 8, 2011 in the District Court of Delaware • Plaintiffs: Abbott Laboratories; Abbott Respiratory LLC • Defendants: Watson Pharmaceuticals Inc.; Watson Laboratories Inc. [read post]
11 Jul 2011, 9:59 pm
Watson Laboratories, Inc. - Florida, the Federal Circuit affirmed a decision by the District Court for the Southern District of Florida holding that Defendant-Appellee Watson Laboratories, Inc. - Florida did not infringe the asserted claims of U.S. [read post]
10 Jul 2011, 9:20 pm
• Defendants: Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Watson Laboratories, Inc. [read post]
8 Jul 2011, 1:13 pm
In 2009, Reckitt Benckiser Inc. sued Watson Laboratories, Inc. - Florida for patent infringement related to Watson's filing of three Abbreviated New Drug Applications for generic versions of Reckitt's Mucinex(R) line of products. [read post]
4 Jul 2011, 9:59 pm
• Defendants: Watson Laboratories Inc.; Watson Pharmaceuticals Inc.; Watson Pharma Inc. [read post]
9 Jun 2011, 10:16 am
Indianapolis, IN - Patent lawyers for Alcon Research Ltd of Fort Worth, Texas, Alcon Pharmaceuticals LTD of Switzerland, and Kyowa Haddo Kirin Co. of Japan filed a patent infringement in alleging Watson Laboratories Inc and Watson Pharma, Inc. of Parsippany, New Jersey, and Watson Laboratories, of Corona, California, infringed the following patent prior to the expiration: Patent No. 5,641,805, Topical ophthalmic formulations for treating… [read post]
9 May 2011, 6:07 am
Albers Medical, Inc., 395 F. [read post]
1 May 2011, 8:45 pm
• Defendants: Watson Pharmaceuticals Inc.; Watson Pharma Inc.; Watson Laboratories Inc. [read post]
12 Apr 2011, 9:37 pm
• Defendants: Watson Laboratories Inc.; Watson Pharmaceuticals Inc.; Watson Pharma Inc. [read post]
6 Apr 2011, 12:18 am
427/09 Generics (UK) Ltd v Synaptech Inc (The SPC Blog) Simcor (Niacin, Simvastatin) – US: Abbott files patent infringement complaint against Watson following Para IV certification filing (Patent Docs) Thalomid (Thalidomide) – US: Decision in Lannett Thalomid bioequivalence study sample antitrust lawsuit could reignite debate on generic drug availability and REMS restrictions (FDA Law Blog) Yasmin (Drospirenone, Ethinylestradiol) – UK: Bayer Yasmin patents survive… [read post]
28 Mar 2011, 9:59 pm
Watson Laboratories, Inc., the Federal Circuit reversed a decision by the District Court for the District of Nevada on summary judgment that the asserted claims of U.S. [read post]
27 Mar 2011, 9:28 pm
Watson Laboratories, Inc. [read post]
25 Feb 2011, 7:12 am
(collectively "Shire") have received a new Paragraph IV Notice Letter from Watson Laboratories, Inc. in Fort Lauderdale, Florida ("Watson") advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of all approved strengths of Shire's ADDERALL XR(R) (mixed salts of a single-entity amphetamine product) dextroamphetamine sulphate, dextroamphetamine saccharate, amphetamine aspartate monohydrate,… [read post]
19 Jan 2011, 2:44 pm
The case goes back to $398 million that Bayer allegedly paid Watson Pharmaceuticals Inc., Barr Laboratories Inc. and others supposedly in exchange for the companies not marketing lower-cost generic versions of the antibiotic Cipro. [read post]
